Hotchkis & Wiley, an investment management firm, recently issued its second-quarter 2026 investor correspondence for its "Mid-Cap Value Fund." The letter highlighted robust equity market performance during the quarter, with the Russell Midcap Index climbing 13.8% and the Russell Midcap Value Index increasing by 13.4%. These gains occurred despite ongoing concerns about inflation, a hawkish Federal Reserve stance, and rising oil prices stemming from geopolitical tensions. The market saw concentrated leadership, particularly from semiconductor and AI-related stocks, which often delivered returns exceeding 100%. Hotchkis & Wiley prioritizes high-quality businesses with attractive valuations, downplaying exaggerated fears surrounding AI's impact. The Mid-Cap Value Fund, however, trailed the Russell Midcap Value Index, achieving a 4.74% return, mainly due to underperformance in the technology and energy sectors, though healthcare selections provided positive contributions.

A key factor in the Mid-Cap Value Fund's positive results for the second quarter of 2026 was the strong performance of Centene Corporation (NYSE:CNC). Centene is a healthcare company based in the U.S., providing services to underinsured and uninsured families, as well as commercial organizations. As of August 3, 2026, Centene's stock closed at $63.76 per share, giving it a market capitalization of $31.49 billion. Over the preceding 52 weeks, Centene's shares saw an impressive gain of 146.27%. The company is recognized for its focus on the Medicaid market, serving approximately 28 million at-risk enrollees and holding one of the largest Medicaid market shares among publicly traded entities. Its business model, characterized by low capital intensity, positions it to benefit from the ongoing shift in U.S. healthcare towards government-funded, cost-controlled initiatives. Centene's exceptional performance in this quarter was driven by adjusted earnings per share that surpassed consensus estimates by 48%, a boosted full-year outlook from management, and increased investor confidence in the recovery of Medicaid margins and the effective reset of Affordable Care Act (ACA) memberships.

Centene Corporation, while delivering strong results, is not featured on our list of the most sought-after stocks among hedge funds entering 2026. Although we recognize its investment potential, we believe that certain AI-focused companies may offer superior growth opportunities with reduced risk. For those seeking an undervalued AI stock poised to benefit from current trade policies and domestic manufacturing trends, a detailed report on the top short-term AI stock is available.

Centene's success highlights the potential for companies to thrive even in complex economic environments, particularly when they effectively adapt to market demands and optimize operational efficiencies. This demonstrates the importance of strategic positioning and responsive management in achieving financial growth and investor confidence, offering a compelling example of resilience and foresight in the healthcare sector.